(NASDAQ: ELTX) Elicio Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.08%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.12%.
Elicio Therapeutics's earnings in 2026 is -$40,185,000.On average, 4 Wall Street analysts forecast ELTX's earnings for 2026 to be -$31,635,179, with the lowest ELTX earnings forecast at -$31,797,411, and the highest ELTX earnings forecast at -$31,062,597. On average, 3 Wall Street analysts forecast ELTX's earnings for 2027 to be -$28,617,670, with the lowest ELTX earnings forecast at -$27,495,408, and the highest ELTX earnings forecast at -$29,459,366.
In 2028, ELTX is forecast to generate -$34,263,333 in earnings, with the lowest earnings forecast at -$32,919,673 and the highest earnings forecast at -$35,271,078.